Aptamer Group PLC
LSE:APTA
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.245
1.3
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| UK |
A
|
Aptamer Group PLC
LSE:APTA
|
25.6m GBP |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
378.8B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
177.8B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
155.1B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.1B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.2B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
85.7B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
47.3B USD |
Loading...
|
Market Distribution
| Min | -188 120% |
| 30th Percentile | 0% |
| Median | 0% |
| 70th Percentile | 0.1% |
| Max | 10 443.9% |
Other Profitability Ratios
Aptamer Group PLC
Glance View
Aptamer Group Plc operates as a biotechnology company. The firm provides custom Optimer selection and development services. The firm provides transformational solutions that meet the needs of researchers and developers across the life sciences through the use of its proprietary Optimer technology. The firm has developed a proprietary platform technology that drives three distinct businesses: Aptamer solutions for custom Optimer development, Aptamer diagnostics for in-house and collaborative Optimer-based diagnostic development and Aptamer therapeutics for the development of Optimer-based therapeutics. Optimer can act as agonists, antagonists or cell-type-specific targeting moieties for the delivery of therapeutic agents to target cells and tissues in the treatment of disease.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Aptamer Group PLC is -2%, which is above its 3-year median of -3.7%.
Over the last 2 years, Aptamer Group PLC’s Net Margin has increased from -4.5% to -2%. During this period, it reached a low of -6.8% on Dec 31, 2023 and a high of -1.9% on Dec 31, 2024.